Impact of Alleles-by-Diet Interactions on Glycemic and Lipid Features- A Cross-Sectional Study of a Cohort of Type 2 Diabetes Patients from Western Mexico: Implications for Personalized Medicine
Overview
Authors
Affiliations
Purpose: To analyze clinically relevant interactions between the apolipoprotein E () ε2, ε3 and ε4 alleles and nutritional factors on glycemic control and lipid levels in a cohort of type 2 diabetes (T2D) patients from western Mexico.
Patients And Methods: In this cross-sectional study of the cohort of T2D patients, a total of 224 individuals were selected for interaction studies. Clinical and anthropometric data were obtained from pre-designed medical records. Dietary intake was assessed by validated three-day food consumption records. Biochemical measurements were determined by automated methods. genotyping was performed by a real-time allelic discrimination assay. Gene-diet interactions were tested by corrected multiple linear regression analyses, which were adjusted by potential confounding factors such as age, sex, energy intake, BMI and anti-hyperglycemic therapy (Metformin, Glibenclamide or Insulin), and years with T2D.
Results: Seventy-six percent of patients with T2D were on Metformin therapy. The frequencies of the alleles were ε2 (5.8%), ε3 (74.1%) and ε4 (20.1%). After statistical settings, significant alleles-by-diet interactions in relation to the metabolic profile were found. Interestingly, higher blood levels of total cholesterol (p int. = 0.016), non-HDL-c (p int. = 0.024), and LDL-c (p int. = 0.030) were found only in carriers of the ε2 allele with a low consumption of MUFA. In contrast, carriers of the ε4 allele with a high ω-6:ω-3 PUFA ratio in the diet had higher %HbA1c blood concentrations (p int. = 0.035).
Conclusion: This study suggests a differential metabolic impact of alleles on lipid/glycemic phenotypes depending on the dietary intake, with important potential implications in the personalized medicine and nutritional management of patients with type 2 diabetes mellitus.
Torres-Vanegas J, Rodriguez-Echevarria R, Campos-Perez W, Rodriguez-Reyes S, Reyes-Perez S, Perez-Robles M Healthcare (Basel). 2025; 13(2).
PMID: 39857130 PMC: 11764561. DOI: 10.3390/healthcare13020103.
Ramos-Lopez O World J Diabetes. 2024; 15(2):142-153.
PMID: 38464367 PMC: 10921165. DOI: 10.4239/wjd.v15.i2.142.
Wuni R, Ventura E, Curi-Quinto K, Murray C, Nunes R, Lovegrove J Front Nutr. 2023; 10:1067033.
PMID: 36776603 PMC: 9909204. DOI: 10.3389/fnut.2023.1067033.
Torres-Valadez R, Roman S, Ojeda-Granados C, Gonzalez-Aldaco K, Panduro A World J Hepatol. 2022; 14(7):1408-1420.
PMID: 36158920 PMC: 9376766. DOI: 10.4254/wjh.v14.i7.1408.
Zepeda-Carrillo E, Ramos-Lopez O, Martinez-Lopez E, Barron-Cabrera E, Bernal-Perez J, Velasco-Gonzalez L Diabetes Metab Syndr Obes. 2022; 15:1771-1784.
PMID: 35711690 PMC: 9196279. DOI: 10.2147/DMSO.S354579.